News
Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...
Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.
The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...
Eli Lilly (LLY) stock recovers as company executives seize a rare buying opportunity to make a series of insider purchases ...
Although new medicines can help you lose weight faster and healthier than ever, a new psychology is needed to keep your ...
Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues
CBER Chief Vinay Prasad reclaimed his job less than two weeks after his mysterious exit; MAHA implementor Gray Delany is out ...
Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...
23h
TipRanks on MSNEli Lilly’s Orforglipron Study: A New Hope for Obesity Treatment?
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company recently completed a ...
Attorney General Paxton argues that the company’s programs and offerings were essentially bribes and resulted in millions in ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results